IBDEI1QD ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,27659,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27659,1,3,0)
 ;;=3^Neuroleptic-Induced Parkinsonism
 ;;^UTILITY(U,$J,358.3,27659,1,4,0)
 ;;=4^G21.11
 ;;^UTILITY(U,$J,358.3,27659,2)
 ;;=^5003772
 ;;^UTILITY(U,$J,358.3,27660,0)
 ;;=G24.01^^113^1347^15
 ;;^UTILITY(U,$J,358.3,27660,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27660,1,3,0)
 ;;=3^Tardive Dyskinesia
 ;;^UTILITY(U,$J,358.3,27660,1,4,0)
 ;;=4^G24.01
 ;;^UTILITY(U,$J,358.3,27660,2)
 ;;=^5003784
 ;;^UTILITY(U,$J,358.3,27661,0)
 ;;=G24.09^^113^1347^16
 ;;^UTILITY(U,$J,358.3,27661,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27661,1,3,0)
 ;;=3^Tardive Dystonia
 ;;^UTILITY(U,$J,358.3,27661,1,4,0)
 ;;=4^G24.09
 ;;^UTILITY(U,$J,358.3,27661,2)
 ;;=^5003786
 ;;^UTILITY(U,$J,358.3,27662,0)
 ;;=G25.1^^113^1347^11
 ;;^UTILITY(U,$J,358.3,27662,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27662,1,3,0)
 ;;=3^Medication-Induced Postural Tremor
 ;;^UTILITY(U,$J,358.3,27662,1,4,0)
 ;;=4^G25.1
 ;;^UTILITY(U,$J,358.3,27662,2)
 ;;=^5003792
 ;;^UTILITY(U,$J,358.3,27663,0)
 ;;=G25.71^^113^1347^14
 ;;^UTILITY(U,$J,358.3,27663,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27663,1,3,0)
 ;;=3^Tardive Akathisia
 ;;^UTILITY(U,$J,358.3,27663,1,4,0)
 ;;=4^G25.71
 ;;^UTILITY(U,$J,358.3,27663,2)
 ;;=^5003799
 ;;^UTILITY(U,$J,358.3,27664,0)
 ;;=G25.79^^113^1347^9
 ;;^UTILITY(U,$J,358.3,27664,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27664,1,3,0)
 ;;=3^Medication-Induced Movement Disorder,Other
 ;;^UTILITY(U,$J,358.3,27664,1,4,0)
 ;;=4^G25.79
 ;;^UTILITY(U,$J,358.3,27664,2)
 ;;=^5003800
 ;;^UTILITY(U,$J,358.3,27665,0)
 ;;=T43.205A^^113^1347^4
 ;;^UTILITY(U,$J,358.3,27665,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27665,1,3,0)
 ;;=3^Antidepressant Discontinuation Syndrome,Init Encntr
 ;;^UTILITY(U,$J,358.3,27665,1,4,0)
 ;;=4^T43.205A
 ;;^UTILITY(U,$J,358.3,27665,2)
 ;;=^5050540
 ;;^UTILITY(U,$J,358.3,27666,0)
 ;;=T43.205D^^113^1347^5
 ;;^UTILITY(U,$J,358.3,27666,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27666,1,3,0)
 ;;=3^Antidepressant Discontinuation Syndrome,Subseq Encntr
 ;;^UTILITY(U,$J,358.3,27666,1,4,0)
 ;;=4^T43.205D
 ;;^UTILITY(U,$J,358.3,27666,2)
 ;;=^5050541
 ;;^UTILITY(U,$J,358.3,27667,0)
 ;;=T43.205S^^113^1347^6
 ;;^UTILITY(U,$J,358.3,27667,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27667,1,3,0)
 ;;=3^Antidepressant Discontinuation Syndrome,Sequela
 ;;^UTILITY(U,$J,358.3,27667,1,4,0)
 ;;=4^T43.205S
 ;;^UTILITY(U,$J,358.3,27667,2)
 ;;=^5050542
 ;;^UTILITY(U,$J,358.3,27668,0)
 ;;=G25.71^^113^1347^7
 ;;^UTILITY(U,$J,358.3,27668,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27668,1,3,0)
 ;;=3^Medication-Induced Acute Akathisia
 ;;^UTILITY(U,$J,358.3,27668,1,4,0)
 ;;=4^G25.71
 ;;^UTILITY(U,$J,358.3,27668,2)
 ;;=^5003799
 ;;^UTILITY(U,$J,358.3,27669,0)
 ;;=G24.02^^113^1347^8
 ;;^UTILITY(U,$J,358.3,27669,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27669,1,3,0)
 ;;=3^Medication-Induced Acute Dystonia
 ;;^UTILITY(U,$J,358.3,27669,1,4,0)
 ;;=4^G24.02
 ;;^UTILITY(U,$J,358.3,27669,2)
 ;;=^5003785
 ;;^UTILITY(U,$J,358.3,27670,0)
 ;;=G21.0^^113^1347^12
 ;;^UTILITY(U,$J,358.3,27670,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27670,1,3,0)
 ;;=3^Neuroleptic Malignant Syndrome
 ;;^UTILITY(U,$J,358.3,27670,1,4,0)
 ;;=4^G21.0
 ;;^UTILITY(U,$J,358.3,27670,2)
 ;;=^5003771
 ;;^UTILITY(U,$J,358.3,27671,0)
 ;;=T50.905A^^113^1347^1
 ;;^UTILITY(U,$J,358.3,27671,1,0)
 ;;=^358.31IA^4^2
